How to Get Repatha in Nevada: Prescriptions, Telehealth, and Prior Authorization

What Repatha Is and Why Nevada Patients Ask About It

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, the enzyme that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors on the cell surface, which pulls more LDL cholesterol out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous FH, homozygous FH, and established ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The landmark FOURIER trial (N=27,564) assigned patients with established ASCVD and LDL-C of at least 70 mg/dL to evolocumab or placebo on top of optimized statin therapy. At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% (from a median of 92 mg/dL to 30 mg/dL, P<0.001) and cut the composite cardiovascular endpoint of MI, stroke, or cardiovascular death by 15% relative to placebo (9.8% vs 11.3%, hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. Those numbers explain why cardiologists across Nevada order it regularly despite the prior-authorization hurdles.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states that a PCSK9 inhibitor is reasonable for patients with established ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [3]. That guideline language is precisely what prescribers copy into prior-authorization letters for Nevada insurers.

Who Can Prescribe Repatha in Nevada

Any licensed Nevada prescriber with full prescriptive authority can write for evolocumab. That includes physicians (MD and DO), nurse practitioners holding a certificate of advanced practice (APRN-C), and physician assistants. Nevada Revised Statutes Chapter 630 governs physician practice, while NRS Chapter 632 governs advanced practice nursing [4]. Nevada APRNs operate under collaborative practice agreements that allow independent prescribing of Schedule II through V controlled substances and non-controlled drugs, so a nurse practitioner at a telehealth platform can legally prescribe Repatha without physician co-signature.

Telehealth prescribing is also explicitly permitted. Nevada SB 391 (2017) and subsequent amendments require telehealth prescribers to establish a valid patient-provider relationship before issuing a prescription, but that relationship can be established entirely through synchronous audio-video consultation [5]. No in-person visit is mandated for evolocumab specifically.

Cardiologists, endocrinologists, lipidologists, and primary care physicians all commonly prescribe PCSK9 inhibitors. If your current prescriber is unfamiliar with the PA process, a telehealth lipid specialist may complete it faster.

Required Labs and Clinical Documentation Before Your Prescription

Prescribers need a clear paper trail before writing the prescription and before the insurer approves it. A fasting lipid panel is the non-negotiable starting point. The ACC/AHA Cholesterol Guideline recommends measuring a fasting or non-fasting lipid panel to establish baseline LDL-C, with a fasting sample preferred when triglycerides are needed for clinical decisions [6].

Beyond the lipid panel, most Nevada commercial insurers and the Amgen specialty pharmacy require:

• A fasting lipid panel drawn within the past 6 to 12 months showing LDL-C at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for FH without ASCVD), obtained while the patient is on maximally tolerated statin therapy
• Documentation of a statin trial. Most payers require at least two statins tried at maximally tolerated doses, typically including a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) [7]
• Evidence of intolerance if the patient is statin-free or on a low dose. Creatine kinase (CK) levels, ALT, AST, and any prior muscle-symptom documentation support an intolerance claim [8]
• Confirmed diagnosis code. ICD-10 E78.01 (familial hypercholesterolemia, heterozygous), E78.02 (FH, homozygous), or a specific ASCVD code (I25.10 for coronary artery disease without angina, I63.x for ischemic stroke, etc.)
• Ezetimibe trial documentation for commercial plans that require triple therapy before approving a PCSK9 inhibitor [9]

Genetic testing for FH (LDLR, APOB, PCSK9 variants) strengthens the case but is not universally required by Nevada payers. The Dutch Lipid Clinic Network score is an alternative when genetic testing is unavailable [10].

How Prior Authorization Works in Nevada

Prior authorization (PA) is the single biggest delay point for Nevada patients. Every major Nevada commercial insurer and all managed-Medicaid plans require PA for evolocumab. Nevada Medicaid fee-for-service does not cover Repatha as of 2024, so fee-for-service Medicaid patients must seek alternative funding.

The PA process follows a predictable sequence:

1. The prescriber submits a PA request with clinical notes, lipid values, statin trial documentation, and the ICD-10 diagnosis code.
2. The plan's pharmacy benefits manager (PBM) reviews the file, typically within 3 to 5 business days for standard review or 24 to 72 hours for urgent review.
3. Approval triggers a specialty pharmacy assignment (usually CVS Specialty, Accredo, or Amgen's own COMPLETE program).
4. Denial triggers an appeal window. Nevada law requires insurers to decide first-level appeals within 30 days for non-urgent cases and 72 hours for urgent cases [11].

The most common denial reasons are insufficient statin trial documentation and missing ezetimibe trial records. Ask your prescriber to include the exact statin names, doses, and duration in the PA letter. A note reading "Patient tried atorvastatin 80 mg daily for 12 weeks and reported myalgia confirmed by CK elevation to 3x ULN" is far more likely to win approval than a generic intolerance claim [12].

For patients facing a second denial, Nevada's independent medical review process allows an external reviewer to overturn the insurer's decision. The Nevada Division of Insurance administers this process [13].

Telehealth Options for Getting Repatha in Nevada

Telehealth prescribing of evolocumab is legal and practical in Nevada. A video consultation with a licensed Nevada prescriber can establish the patient-provider relationship, review existing lab results, generate the prescription, and submit the prior-authorization paperwork in a single session.

Several national telehealth platforms operate in Nevada and have prescribers credentialed to prescribe specialty medications including PCSK9 inhibitors. HealthRX connects Nevada patients with board-certified clinicians who specialize in lipid management and can handle the full PA workflow on the patient's behalf. The typical timeline from first telehealth consult to drug-in-hand runs 14 to 28 days, with most of that time consumed by the insurer's PA review.

Synchronous audio-video is required for the initial prescribing visit under Nevada telehealth law. Asynchronous (store-and-forward) visits alone are not sufficient to initiate a new prescription for a specialty drug like evolocumab [5]. Follow-up visits and prescription renewals may use asynchronous communication once the relationship is established.

Patients in rural Nevada counties (Elko, Lander, Eureka, Mineral) gain the most from telehealth access because the nearest lipidologist may be 200 or more miles away in Las Vegas or Reno. The Nevada Office of Rural Health reports that 14 of Nevada's 17 counties are designated as Health Professional Shortage Areas for primary care [14].

Pharmacy Access: Specialty Dispensing and 503A Compounding in Nevada

Evolocumab is a biologic, not a small-molecule drug, so it cannot be identically reproduced by a compounding pharmacy. However, Nevada's licensed 503A compounding pharmacies can prepare other lipid-lowering formulations (such as customized statin suspensions for patients with swallowing difficulties) and can handle the logistics of specialty drug coordination.

For branded Repatha specifically, dispensing occurs through specialty pharmacies. Amgen's COMPLETE program ships directly to patients anywhere in Nevada, including rural ZIP codes. CVS Specialty and Accredo are the two PBMs most commonly contracted by Nevada commercial plans. All three ship temperature-controlled packages with gel packs; Repatha must be stored at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and can remain at room temperature (up to 77 degrees Fahrenheit / 25 degrees Celsius) for up to 30 days [1].

503A pharmacies in Nevada are licensed by the Nevada State Board of Pharmacy and may dispense patient-specific, non-sterile or sterile compounded preparations. They cannot compound a biosimilar version of evolocumab for individual patients without FDA approval of that biosimilar. As of 2024, no evolocumab biosimilar holds FDA approval, though multiple candidates are in Phase 3 trials [15].

Cost Assistance Programs for Nevada Patients

List price for Repatha runs approximately $700 per month, though few commercially insured patients pay that figure. Nevada patients have access to several cost-reduction pathways:

Amgen's REPATHA COPAY CARD reduces out-of-pocket costs to as low as $5 per month for eligible commercially insured patients [16]. The card is not valid for Medicare or Medicaid beneficiaries.

The Amgen Safety Net Foundation provides free Repatha to uninsured or underinsured Nevada patients who meet income criteria (generally at or below 500% of the federal poverty level) [17].

Medicare Part D patients can use the Extra Help (Low Income Subsidy) program to reduce specialty tier costs [18]. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, which takes effect in 2025, will substantially lower yearly costs for Medicare beneficiaries who need PCSK9 inhibitors.

For patients whose insurers deny coverage entirely, an appeals strategy grounded in the ACC/AHA guideline language and FOURIER outcomes data wins a meaningful share of second-level appeals. One specialty pharmacy advocacy study found that PCSK9 inhibitor PA approval rates increased from 52% on initial submission to 76% after one appeal when complete clinical documentation was provided [19].

Transferring an Existing Repatha Prescription to Nevada

Patients relocating to Nevada from another state can transfer an existing Repatha prescription if the prescribing provider is licensed in Nevada or if a Nevada-licensed prescriber reissues the prescription. Specialty pharmacy fills typically run in 28-day or 30-day cycles. Because evolocumab is not a controlled substance, Nevada pharmacies and specialty pharmacies can accept transferred prescriptions without the additional restrictions that apply to Schedule II drugs [20].

The transfer process involves four steps. First, contact the specialty pharmacy and request a state transfer. Second, have your new Nevada prescriber (or telehealth provider) confirm coverage of clinical management. Third, confirm that your insurance plan's specialty pharmacy network includes a Nevada-accessible dispenser. Fourth, re-verify PA status, because some plans require a new PA when the prescribing physician changes. Re-authorization requests typically take 3 to 5 business days [11].

Patients who moved and whose PA has already expired should request a PA renewal simultaneously with the prescription transfer to avoid a gap in therapy. A lapse of more than 30 days at room temperature or any freeze-thaw cycle renders a Repatha pen or SureClick autoinjector unusable [1].

Monitoring and Follow-Up After Starting Repatha in Nevada

Evolocumab does not require routine liver function monitoring or CK monitoring the way older lipid agents did. The FDA label recommends a fasting lipid panel 4 to 8 weeks after initiating therapy or adjusting dose to confirm LDL-C response [1]. In FOURIER, the mean LDL-C at week 4 already reflected most of the eventual LDL reduction, so an early draw at 4 weeks is diagnostically useful [2].

Nevada telehealth providers can order follow-up labs through any CLIA-certified laboratory in the state, including LabCorp and Quest Diagnostics, which have patient service centers in Las Vegas, Reno, Henderson, and Carson City. Results route directly to the telehealth prescriber's electronic health record for review.

For patients with homozygous FH, the ACC/AHA guidelines recommend a more aggressive LDL-C target of below 70 mg/dL and may warrant LDL apheresis referral if pharmacotherapy alone is insufficient [6]. The University of Nevada Las Vegas School of Medicine and Renown Regional Medical Center in Reno both have lipid programs that can coordinate apheresis for homozygous FH patients in the state.

After the first two follow-up lipid panels confirm a stable LDL-C response, most Nevada prescribers and telehealth platforms move patients to annual lipid monitoring with prescription renewals issued every 12 months. Each renewal may require a new PA depending on the insurer's PA duration policy; Nevada commercial plans commonly grant 12-month PA periods for PCSK9 inhibitors [11].

The 2023 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines state that "for very-high-risk patients, an LDL-C reduction of at least 50% from baseline and an LDL-C goal of <55 mg/dL (1.4 mmol/L) is recommended," a target that frequently requires PCSK9 inhibitor therapy in addition to high-intensity statins [21]. For Nevada patients with recent ACS, that 55 mg/dL ceiling shapes the PA justification letter more effectively than quoting the older 70 mg/dL threshold.